REnal Disease ( FAVOURED ) study

Background: Haemodialysis (HD) is critically dependent on the availability of adequate access to the systemic circulation, ideally via a native arteriovenous fistula (AVF). The Primary failure rate of an AVF ranges between 20–54%, due to thrombosis or failure of maturation. There remains limited evidence for the use of anti-platelet agents and uncertainty as to choice of agent(s) for the prevention of AVF thrombosis. We present the study protocol for a randomised, double-blind, placebo-controlled, clinical trial examining whether the use of the anti-platelet agents, aspirin and omega-3 fatty acids, either alone or in combination, will effectively reduce the risk of early thrombosis in de novo AVF. Methods/Design: The study population is adult patients with stage IV or V chronic kidney disease (CKD) currently on HD or where HD is planned to start within 6 months in whom a planned upper or lower arm AVF is to be the primary HD access. Using a factorial-design trial, patients will be randomised to aspirin or matching placebo, and also to omega-3 fatty acids or matching placebo, resulting in four treatment groups (aspirin placebo/omega-3 fatty acid placebo, aspirin/omega-3 fatty acid placebo, aspirin placebo/omega-3 fatty acid, aspirin/omega-3 fatty acid). Randomisation will be achieved using a dynamic balancing method over the two stratification factors of study site and upper versus lower arm AVF. The medication will be commenced pre-operatively and continued for 3 months post surgery. The primary outcome is patency of the AVF at three months Published: 21 January 2009 BMC Nephrology 2009, 10:1 doi:10.1186/1471-2369-10-1 Received: 7 December 2008 Accepted: 21 January 2009 This article is available from: http://www.biomedcentral.com/1471-2369/10/1 © 2009 Irish et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

[1]  G. Beck,et al.  Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. , 2008, JAMA.

[2]  G. Eknoyan,et al.  Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[3]  Prabir Roy-Chaudhury,et al.  Early arteriovenous fistula failure: a logical proposal for when and how to intervene. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[4]  S. Moe,et al.  Review of the effects of omega-3 supplementation in dialysis patients. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[5]  R. Foley,et al.  Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. , 2005, Kidney international.

[6]  M. Landray,et al.  First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Marcello Tonelli,et al.  Establishment and maintenance of vascular access in incident hemodialysis patients: a prospective cost analysis. , 2004, Journal of the American Society of Nephrology : JASN.

[8]  T. Stijnen,et al.  Radiocephalic wrist arteriovenous fistula for hemodialysis: meta-analysis indicates a high primary failure rate. , 2004, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[9]  Trevor A. Mori,et al.  Effect of fish and fish oil-derived omega-3 fatty acids on lipid oxidation , 2004, Redox report : communications in free radical research.

[10]  L. Beilin,et al.  Omega-3 fatty acids and inflammation , 2004, Current atherosclerosis reports.

[11]  R. Atkins,et al.  Vascular access and all-cause mortality: a propensity score analysis. , 2004, Journal of the American Society of Nephrology : JASN.

[12]  G. Watts,et al.  Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. , 2002, The American journal of clinical nutrition.

[13]  M. Robbin,et al.  Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. , 2002, Kidney international.

[14]  W. McClellan,et al.  Vascular access and increased risk of death among hemodialysis patients. , 2002, Kidney international.

[15]  G. Watts,et al.  Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity , 2002, European journal of clinical investigation.

[16]  K. Kent,et al.  Recommended standards for reports dealing with arteriovenous hemodialysis accesses. , 2002, Journal of vascular surgery.

[17]  T. Saldeen,et al.  Effect of low-dose aspirin in combination with stable fish oil on whole blood production of eicosanoids. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.

[18]  F. D. de Abajo,et al.  Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations , 2001, BMC clinical pharmacology.

[19]  M. Metcalfe,et al.  Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation , 2001, The British journal of surgery.

[20]  P. Morris,et al.  Low dose aspirin as prophylaxis against renal-vein thrombosis in renal-transplant recipients. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  P. Khajehdehi Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. , 2000, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[22]  G. Watts,et al.  Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Vascular Reactivity of the Forearm Microcirculation in Hyperlipidemic, Overweight Men , 2000, Circulation.

[23]  G. Watts,et al.  Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. , 2000, The American journal of clinical nutrition.

[24]  J. Kaufman Antithrombotic Agents and the Prevention of Access Thrombosis , 2000, Seminars in dialysis.

[25]  H. Nihei,et al.  Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[26]  R. Gokal,et al.  Haemodialysis , 1999, The Lancet.

[27]  O. Al‐Shabanah,et al.  Effect of acute administration of fish oil (omega-3 marine triglyceride) on gastric ulceration and secretion induced by various ulcerogenic and necrotizing agents in rats. , 1995, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[28]  C. Rogers,et al.  DIET, ULCER DISEASE, AND FISH OIL , 1988, The Lancet.

[29]  M. Bonati,et al.  Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. , 1987, The Journal of clinical investigation.

[30]  G. Remuzzi,et al.  MODERATE DOSES OF ASPIRIN AND RISK OF BLEEDING IN RENAL FAILURE , 1986, The Lancet.

[31]  E. Ritz,et al.  Prevention of p.o. clotting of av. cimino fistulae with Acetylsalicyl acid results of a prospective double blind study , 1974, Klinische Wochenschrift.

[32]  G. Watts,et al.  Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. , 2003, Atherosclerosis.

[33]  L. Beilin,et al.  Dietary w3 fatty acids , 2003 .

[34]  M. Gellens,et al.  Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. , 2002, Journal of the American Society of Nephrology : JASN.

[35]  H. Mulec,et al.  Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. , 1998, Scandinavian journal of urology and nephrology.

[36]  J. Marx,et al.  Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  C. Zellner,et al.  Fish oil to prevent intimal hyperplasia and access thrombosis. , 1990, Nephron.